Roche Diagnostics secured FDA clearance for its Cobas Respiratory 4-flex assay, which simultaneously detects SARS-CoV-2, influenza A/B, and RSV on high-throughput Cobas platforms. The test employs innovative Temperature-Activated Generation of Signal (TAGS) technology, enhancing multiplexing capacity in a single optical channel. The digital reflex option enables additional results from the same run, facilitating diagnostic stewardship. Roche highlights its suitability amid shifting respiratory virus patterns, aiming to empower labs with flexible, reliable testing options.